Shares of GlaxoSmithKline plc (NYSE:GSK) have earned a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $41.00.
A number of research analysts recently commented on GSK shares. Berenberg Bank reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 19th. Barclays reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research note on Monday, July 19th. UBS Group reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, September 20th. Zacks Investment Research cut GlaxoSmithKline from a “hold” rating to a “sell” rating and set a $41.00 price objective on the stock. in a research note on Tuesday, July 20th. Finally, Credit Suisse Group reaffirmed an “underperform” rating on shares of GlaxoSmithKline in a research note on Thursday, June 24th.
Shares of GSK stock opened at $38.80 on Monday. The company has a market capitalization of $104.47 billion, a PE ratio of 16.37, a price-to-earnings-growth ratio of 2.10 and a beta of 0.70. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.53 and a current ratio of 0.82. GlaxoSmithKline has a 52-week low of $33.26 and a 52-week high of $42.68. The business’s fifty day moving average is $40.03 and its 200 day moving average is $39.20.
The company also recently announced a quarterly dividend, which was paid on Thursday, October 7th. Stockholders of record on Friday, August 20th were issued a dividend of $0.523 per share. The ex-dividend date of this dividend was Thursday, August 19th. This represents a $2.09 dividend on an annualized basis and a dividend yield of 5.39%. GlaxoSmithKline’s dividend payout ratio is currently 68.46%.
Institutional investors and hedge funds have recently modified their holdings of the business. Evermay Wealth Management LLC purchased a new position in shares of GlaxoSmithKline during the second quarter valued at approximately $26,000. Reilly Financial Advisors LLC lifted its holdings in shares of GlaxoSmithKline by 131.7% during the second quarter. Reilly Financial Advisors LLC now owns 695 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 395 shares during the last quarter. Evoke Wealth LLC lifted its holdings in shares of GlaxoSmithKline by 152.6% during the first quarter. Evoke Wealth LLC now owns 730 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 441 shares during the last quarter. RMR Wealth Builders lifted its holdings in shares of GlaxoSmithKline by 67.1% during the first quarter. RMR Wealth Builders now owns 752 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 302 shares during the last quarter. Finally, SRS Capital Advisors Inc. purchased a new position in shares of GlaxoSmithKline during the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 12.25% of the company’s stock.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
Featured Story: What is dollar cost averaging (DCA)?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.